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Objective: Inhibition of early myointimal proliferation may improve long- 
term patency of vein grafts, but the clinical use of many experimental drugs 
is limited by systemic toxicity. To determine whether this goal can be 
achieved by low-dose targeted drug administration, we constructed a 
polymeric system delivering verapamil and evaluated the effects on local 
and downstream vein graft morphology, neointimal smooth muscle cell 
proliferation, and vasomotor function. Methods: Ethylene-vinyl acetate 
polymeric delivery systems were constructed, containing 2% verapamil by 
weight. These are flexible, biocompatible, and nonbiodegradable matrices, 
delivering the drug at a rate of 10/zg/day. The autologous external jugular 
vein was used to create a carotid artery bypass graft in hypercholester- 
olemic (n = 22) rabbits. Verapamillcontaining matrices (n = 12) or plain 
polymers (control, n = 10) were wrapped around the proximal third of the 
veins after reperfusion. Graft vasomotor function was evaluated and was 
also compared with function of an additional group of normocholesterl 
olemic vein grafts (n = 8). Results: Twenty-eight days after grafting, intimal 
index (intima/media thickness ratio) was 31% lower, neointima/original 
lumen surface ratio was 26% lower, and residual uminal area was 71% 
greater (4.00 - 1.2 mm z versus 2.34 - 0.9 mm 2, all p < 0.01) under 
verapamil matrices compared with control grafts. Neointimal smooth 
muscle cell content was reduced from 45.4% to 28.2%, and net neointimal 
smooth muscle cell thickness was reduced by 47% (30/xm vs 15.8 pm, both 
p < 0.01). Verapamil-treated segments distal to the matrices also showed 
significantly lower neointimal smooth muscle cell density and increased 
lumen size. Sensitivity to serotonin and vasomotor responses to serotonin, 
norepinephrine, and sodium nitroprusside in distal segments were signif- 
icantly lower in verapamil-treated grafts than in controls. Conclusions: 
Periadventitial controlled administration of verapamil below 1% of the 
systemic dose effectively inhibits myointimal hyperplasia in vein grafts. 
Local polymeric drug delivery may be readily applicable to coronary 
revascularization perations. (J Thorac Cardiovasc Surg 1997;114:53-63) 
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A utologous saphenous veins remain the most widely used conduits for coronary revasculariza- 
tion, but their long-term patency is limited by the 
development of atherosclerosis. This leads to occlu- 
sion of up to 50% of vein grafts within 10 years and 
to atherosclerotic disease in 13% of patent grafts at 
3 years, 27% at 8 years, and 50% at 12 years. 1Early 
morphologic hanges in arterialized veins include 
the development of intimal hyperplasia, which may 
constitute the substrate for subsequent development 
of accelerated atherosclerosis. 2' 3 Although this is 
initially a remodeling process precipitated by the 
altered hemodynamic conditions in the arterial cir- 
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culation and by resulting endothelial damage, inti- 
mal hyperplasia may also result in significant lumi- 
nal narrowing and graft failure. Interference with 
the early proliferative phase of neointima formation 
may delay the occurrence of vein graft atheroscle- 
rosis and improve long-term patency. 
Many systemically administered pharmacologic 
agents have been shown to inhibit intimal hyperpla- 
sia in experimental vein grafts. However, some of 
the more potent drugs (e.g., antimetabolites) have 
severe systemic side effects at the dose required to 
achieve an efficient vascular effect, whereas others 
are not readily absorbed after oral intake or have a 
short plasma half-life. 4 A targeted drug delivery 
system acting on the grafted conduit may circumvent 
these limitations by achieving high drug concentra- 
tions locally. Such systems typically deliver 1% or 
less of the systemic drug dose, minimizing side 
effects and increasing cost-effectiveness. 5 In coro- 
nary surgical revascularization, the application of a 
local drug release system at the time of the opera- 
tion seems particularly attractive: in addition to the 
benefits of targeted rug delivery, a nonabsorbable 
polymer may protect the conduit from accidental 
injury and facilitate dissection in the event of rest- 
ernotomy. Rigid external support may confer an 
additional local inhibitory effect on intimal hyper- 
plasia. 6A distal downstream effect is also desirable, 
because it would enable application of the device to 
proximal segments of the conduit only, avoiding the 
need for matrix modeling. Finally, this strategy does 
not require patient compliance and may therefore 
benefit older or disabled patients who require cor- 
onary artery bypass grafting. 
Ethylene-vinyl acetate (EVA)-based periadventi- 
tial matrices delivering heparin 7 and more recently 
AG-17, an inhibitor of protein tyrosine kinase activ- 
ity, 8 were shown to inhibit neointimal formation in 
the balloon carotid arterial injury model in rats. 
Other polymeric extraluminal delivery systems have 
been successfully used in arterial injury models 
when systemic administration was ineffective. 9' 10 
Verapamil, a widely used calcium-channel blocker, 
was previously shown to inhibit intimal hyperplasia 
in normocholesterolemic rabbit arterialized vein 
grafts. 11 Although their precise mechanism of action 
is unknown, this and other calcium-channel blockers 
have been reported to interfere with vascular 
smooth muscle cell (SMC) proliferation and migra- 
tion induced by platelet-derived growth factor 
(PDGF) in vitro. 12 Moreover, a decrease in cellular 
lipid content was attributed to verapamil stimulation 
of cholesteryl ester hydrolase activity in SMCs, and 
inhibition of vascular SMC proliferation and migra- 
tion was observed in rabbits. 13' 14 
In the present study we constructed a periadven- 
titial polymeric system delivering verapamil and 
evaluated its ability to affect early vein graft myointi- 
mal proliferation, lipid accumulation, and vasomo- 
tor function in hypercholesterolemic rabbits. We 
also sought o determine whether an effect would be 
limited to the graft segment directly under the 
polymer or whether it could also be detected own- 
stream. 
Materials and methods 
Polymeric drug delivery system. EVA copolymer (E1- 
vax 40, DuPont Pharmaceuticals, Wilmington, Del.) was 
washed with water and alcohol to remove impurities. I5
Verapamil hydrochloride (Sigma Chemical Co., St. Louis, 
Mo.) and EVA were dissolved in methylene chloride, 
yielding a 15% wt/vol solution as described previously, s'is 
The solution was poured into glass Petri dishes and dried. 
The east polymeric matrix (0.2 mm thick) was cut into 
circular pieces (0.79 cm 2) for in vitro release studies and 
into rectangular pieces (2 × 0.7 cm and weighing 100 rag) 
for perivascular implantation. Unidirectional release of 
the drug was achieved by sealing one surface of the 
matrices with blank EVA film using a few drops of 
methylene chloride as glue. The resulting delivery system 
is a flexible transparent matrix having the advantages of 
being biocompatible and nondegradable. 15 Before im- 
plantation the matrices were sterilized with ethylene 
oxide. 
Drug release kinetics. Release kinetics were measured 
in this fashion: Two circular pieces of sealed verapamil 
matrices were separated by aluminum foil and mounted 
back to back between two halves of a diffusion cell as 
described previously, s The cells were filled with HEPES 
buffer, pH 7.4, placed in a shaker at 37 ° C, and the amount 
released from each matrix over time was measured in the 
receiving solution by spectrophotometry at 233 nm. To 
keep sink conditions (maximum concentration f 10% of 
saturation), we replaced the receiving liquid at each time 
point with fresh buffer. 
Animal model. Thirty New Zealand White rabbits 
weighing 4 to 4.5 kg (Irish Farms, Norco, Calif.) were used 
to create xperimental vein bypass grafts of the common 
carotid artery. Anesthesia was induced intravenously with 
ketamine (10 mg/kg) and acepromazine (1 mg/kg) and 
maintained with inhaled 1.5% isoflurane in oxygen by 
means of mechanical ventilation. Heparin (200 mg/kg) 
and cefazolin (40 mg/kg) were administered intravenously 
before incision. Exposure and dissection of the left exter- 
nal jugular vein and common carotid artery were com- 
pleted by way of a paramedian neck incision. A segment of 
the vein extending cephalad from the junction of the 
external and internal jugular veins (2.5 cm long) was 
excised and preserved in lactated Ringer's solution with 
papaverine (0.8 mg/ml). Proximal and distal anastomoses 
were performed in an end-to-side fashion with 8-0 
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polypropylene sutures (Deknatel Inc., Division of DSP 
Worldwide, Fall River, Mass.). The bypassed carotid 
artery segment was excised and graft patency was con- 
firmed by ultrasonic flow measurement (Transonic Sys- 
tems, Inc., Ithaca, N.Y.). Hypercholesterolemic rabbits 
(n = 22) received a 1% cholesterol-supplemented di t
(Newco, Fontana, Calif.), which was started 28 days 
before the operation and continued throughout the study. 
These animals were randomized to receive polymeric 
EVA matrices containing verapamil (n = 12) or control, 
plain polymers (n = 10). After completion of the anasto- 
moses and restoration of flow, the polymer patches were 
applied around the proximal third of the grafts and the 
free edge was approximated with a 6-0 polypropylene 
suture, care being taken not to compress or deform the 
vein (Fig. 1). The matrices were anchored to the proximal 
carotid artery stump to prevent distal migration of the 
polymer. An additional group of normocholesterolemic 
rabbits (n = 8) had similar procedures but no polymer 
implantation. The skin was closed with 3-0 Dexon suture 
(Davis & Geck, Danbury, Conn.). All animals were 
treated in compliance with the "Principles of Laboratory 
Animal Care" formulated by the National Society for 
Medical Research and the "Guide for the Care and Use of 
Laboratory Animals" prepared by the Institute of Labo- 
ratory Animal Resources and published by the National 
Institutes of Health (NIH Publication No. 86-23, revised 
1985). 
Specimen processing. Twenty-eight days after the op- 
eration, animals were put to death and graft tissue was 
collected for morphometric and vasomotor analysis. Vein 
graft regions within 3 mm of the proximal or distal suture 
lines were discarded. Specimens were divided into the 
experimental groups as follows: HC~ont,ol--hypercholes- 
terolemic rabbits, proximal graft segments directly under 
control EVA polymers; HCVp,oximal--hypercholester- 
olemic rabbits, proximal graft segments directly under 
verapamil matrices; and HCVaistal--hypercholester- 
olemic rabbits, graft segments at least 4 mm distal to the 
verapamil matrices. Normocholesterolemic (NC) vein 
graft midsegments were used for vasomotor studies only. 
Tissue processing personnel were blinded to the experi- 
mental protocol. 
For light microscopy, graft rings from under the poly- 
mer and from distal area midsegments were fixed in 10% 
formalin for at least 24 hours and then embedded in 
paraffin. Ten-micron sections were cut perpendicular to 
the vessel wall and then stained with Masson's trichrome 
stain. Four to eight separate sections of each segment 
(under and distal to the polymers) at 200 txm intervals 
were analyzed and average values were derived for each 
specimen. Morphometric measurements of average inti- 
real and medial thickness and areas, as well as lumen 
contour length, were obtained by means of computed 
image analysis software (Timwin, TEA, Dordrecht, The 
Netherlands). Residual l minal area was calculated from 
the lumen contour. The degree of neointimal thickening 
was expressed as (1) the ratio of the neointimal area and 
the original uminal area as defined by the outer neointi- 
mal margin (percent stenosis) and (2) the ratio of the 
neointimal and medial surfaces (intimal index). 
Fig. 1. & Placement of a verapamil-EVA polymeric ma- 
trix around the proximal third of a jugular vein graft 
bypassing the carotid artery. The matrix is flexible and 
provides good suture handling. B, Final appearance of the 
graft with the matrix in place. Anchoring the polymer to 
the proximal carotid stump (not seen) prevents distal 
migration. At reoperation, dissection was facilitated by 
the presence of the device. 
For transmission electron microscopy, graft rings were 
immersed in 2.5% glutaraldehyde and 2% paraformalde- 
hyde buffered by sodium cacodylate. Tissue was then 
postfixed in 1% osmium, dehydrated, and embedded in an 
epoxy resin. One-micron sections tained with toluidine 
blue were initially reviewed in a blinded fashion toidentify 
intimal areas suitable for ultrastructural study. Uitrathin 
sections were stained with uranyl acetate and lead citrate. 
Electron micrographs were prepared on a Zeiss EM 109 
electron microscope (Carl Zeiss Inc., Thornwood, N.Y.) 
and printed at a final magnification of x3000. Twelve to 
sixteen random nonadjacent captures within intimal areas 
were analyzed for each specimen. SMCs were identified 
by the characteristic appearance of actin filaments with 
mostly peripheral ocal densities, by the presence of a 
discontinuous external lamina and dense rough endoplas- 
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Fig. 2. Release kinetics of EVA polymeric systems (0.2 mm thick) containing 0.5% or 2% wt/wt of 
verapamil. Two percent verapamil matrices were used in the present study. Drug release rate decreases 
over time, with an initially high delivery rate that may be beneficial at the early stages of vascular injury. 
mic reticulum, and by the absence of lysosomes. To 
determine intimal SMC content, we subjected the photo- 
graphs to computer-assisted morphometric examination 
(Timwin, TEA) and the fractional area occupied bySMCs 
(SMC density) was determined. An estimate of the abso- 
lute mass of SMCs and matrix in the graft intima was thus 
obtained. 
Ex vivo isometric vasomotor studies. Vein graft seg- 
ments measuring 4 to 5 mm were collected from the distal 
portion of the grafts, ending at least 3 mm proximal to the 
distal anastomosis site, and were immediately placed in 
oxygenated Krebs solution (millimolar concentrations: 
NaC1 118; KC1 4.7; MgSO 4 1.2; CaC12 2.5; NaHCO3 25; 
KH2PO 4 1.2, glucose 11.5). The solution was continuously 
oxygenated with a 95% oxygen and 5% carbon dioxide gas 
mixture and maintained at 37°C throughout the experi- 
ment. The rings were suspended on two stainless steel 
hooks in 25 ml tissue baths (Radnoti Glass Technologies, 
Monrovia, Calif.) with one hook fixed to the bottom of the 
bath and the other connected to a multichannel polygraph 
recorder (Grass Instruments Inc., Quincy, Mass.), then set 
at a tension of 1 gm and allowed to equilibrate for 1 hour, 
while the Krebs solution was replaced every 20 minutes. 
After equilibration, the optimal resting tension for maxi- 
mal response was determined by recording the contractile 
response to a Krebs solution with a KC1 concentration of
60 mmol/L at different resting tensions, ranging from 0.5 
to 2.5 gm in 0.5 gm increments. The tension at which a 
ring generated the maximal contraction was considered to 
be the optimal resting tension for that ring, and the ring 
was set at that tension for subsequent studies. After 
washouts and equilibration, dose-response curves were 
obtained for cumulative doses of serotonin (10 s to 10 -4  
tool/L) and norepinephrine (10 s to 10 -4  mol/L). After 
the grafts had been precontracted to 80% of the maximal 
tension generated to norepinephrine, the relaxation re- 
sponse to sodium nitroprusside (10-12 to 10 .8 mol/L) was 
determined. All chemicals were purchased from Sigma 
Chemical Co., St. Louis, Missouri, and were dissolved in 
distilled water. 
Data analysis. Isometric responses of the vein rings (in 
milligrams of generated force) were adjusted to the 
maximal ring contraction to a Krebs buffer solution with a 
60 mmolfL concentration f KC1 and expressed as per- 
centage of the maximal response. The agonist concentra- 
tion at which half-maximal contraction or relaxation oc- 
curred (ED5o) was calculated from the response curves by 
logistic analysis. Graft sensitivity to each agonist was 
defined as -loglo(ECso ). Data are expressed as mean _+ 
standard eviation of the mean. Comparisons of morpho- 
metric data from local and distal verapamil-treated seg- 
ments and from control segments were made by one-way 
analysis of variance, and significant differences were ana- 
lyzed with Dunnett's post hoc test for multiple compari- 
sons. Sensitivity and contraction responses in verapamil- 
treated vein grafts were compared with control responses 
by means of the two-tailed Student's t test. Significance 
level was set at p < 0.05. 
Resul ts  
Verapamil delivery system. EVA matrices con- 
taining verapamil were homogeneous,  and examina- 
tion of their structure by scanning electron micros- 
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copy did not detect any drug crystals or particles, 
which suggests that an amorphous dispersion of 
verapamil in the polymer is produced when the 
agent and EVA are cast from methylene chloride 
solution. The drug release kinetics and the effect of 
drug load concentration on the release rate kinetics 
were determined to enable a rational design of a 
drug delivery system responding to the therapeutic 
results in vivo. Matrices loaded with 0.5% and 2% 
wt/wt released the drug in an exponential manner, 
that is, release rate decreased over time (Fig. 2). As 
seen, the fraction released over time is affected by 
the drug load: after 24 days, 13% and 34% of the 
drug load was released from 2% and 0.5% matrices, 
respectively. On the basis of these results, matrices 
containing 2% verapamil and releasing approxi- 
mately 10/xg/day were used for in vivo implantation 
studies. 
Reoperation. The cholesterol-supplemented di t 
was well tolerated by all animals. Serum cholesterol 
levels at time of the initial operation and before the 
animals were put to death were 1460 _+ 384 mg/dl. 
At reoperation, all grafts were found to be patent 
and no distal migration of the EVA polymers was 
noted. Adhesions formed around the grafts in all 
animals; however, hypercholesterolemic rabbits 
were noted to have denser adhesions and more lipid 
deposition in subcutaneous tissues. Ix)calization, 
exposure, and dissection of the grafts were greatly 
facilitated by the presence of EVA polymers. 
Whereas dense adhesions formed around the un- 
wrapped segments of all grafts, connective tissue 
around the EVA matrices did not adhere to the 
biocompatible polymers, and these could be easily 
mobilized. No inflammatory esponse or granulation 
tissue developed. In the wrapped region of the 
grafts, the presence of EVA matrices virtually elim- 
inated the danger of inadvertent injury to the vessel 
during reoperation. The matrices did not constrict 
the grafts, and adhesions did not form between the 
graft adventitia nd the inner polymer surface. After 
removal of the polymers, the demarcation li e be- 
tween the area beneath and distal to the matrices 
could be seen and was used to determine the 
respective areas for specimen collection. 
Morphology. The neointima consisted of prolif- 
erated SMCs ("myointimal cells"), lipid-laden 
phagocytic ells, and a loose extracellular matrix. 
Representative photomicrographs of HCcontrol, 
HCVproxirnal, and HCVdistal segments are shown in 
Fig. 3, and wall cross sections are shown in Fig. 4. 
The effects of verapamil treatment on vein graft 
Fig. 3. Representative photomicrographs of vein graft 
segments directly under plain control EVA polymers (A), 
under verapamil-EVA matrices (B), and distal segments 
of verapamil-treated grafts (C). 
remodeling 28 days after the operation are shown in 
Table I. The intimal index and percent stenosis 
under the polymer decreased significantly, reflecting 
an inhibitory effect on intimal thickening. A 20% 
decrease in average intimal width (314 +_ 68/xm vs 
392 _+ 122 /xm) was also observed but was not 
statistically significant. These effects were not ob- 
served distal to the polymers. However, residual 
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Fig. 4. Cross sections of the vein graft wall under control EVA (A), under verapamil-EVA (B), and 
downstream ofverapamil-EVA polymeric matrices (C). N/, Neointima; M, media. 
Table I. Morphometric analysis of proximal and downstream verapamil-treated and control vein graft segments 
H C control H C Vproximal H CVdistal 
Intimal index 2.83 _+ 0.49 1.94 _+ 0.46* 2.63 + 0.61 
Percent stenosis 50.0 _+ 8 37.1 _+ 7* 50.4 + 6 
Luminal area (mm 2) 2.34 + 0.92 4.00 -4- 1.25" 3.37 + 0.51" 
HCcon~ot, Hypercholesterolemic vein graft segments und r empty polymers; HCVproxlmal nd HCVdistal, hypercholesterolemic vein graft segments und r and 
distal to verapamil-EVA polymers. Values are the mean _+ standard deviation. 
*p < 0.01 compared with HCcontro l grafts. 
luminal area was significantly greater in both the 
wrapped and distal segments in the verapamil- 
treated group. 
Representative electron micrographs of intimal 
cross sections from HCcontrol, HfVprox imal  , and 
HCVdistal vein grafts are shown in Fig. 5. Neointimal 
SMC density (percent SMC surface from total area) 
was significantly lower in verapamil-treated grafts, 
an effect observed both under the polymers and 
downstream. When excluding extracellular matrix 
and foam cells, the amount of net intimal SMC 
(defined as SMC density × mean intimal thickness) 
was also significantly lower under the verapamil 
matrices. Despite the lower SMC density distal to 
the EVA polymers, the net mass of neointimal SMC 
was not significantly lower in this area of the graft. 
This was due to the greater average intimal thick- 
ness resulting from significantly higher lipid and 
foam cell accumulation i the distal segments (Table 
II). 
Vasomotor function. Isometric tension studies 
were performed on vein graft segments distal to the 
polymeric matrices, and an additional group of 
normocholesterolemic vein grafts were used for 
comparison. As can be seen in Table III, hypercho- 
lesterolemia significantly increased vein graft sensi- 
tivity to serotonin and decreased graft sensitivity to 
sodium nitroprusside. A lower sensitivity to norepi- 
nephrine was also observed but the difference was 
not statistically significant. The effects of hypercho- 
lesterolemia on serotonin and norepinephrine sen- 
sitivity were reversed by verapamil treatment o 
levels resembling those of normocholesterolemic 
vein grafts. The lower sensitivity to sodium nitro- 
prusside was not significantly affected by verapamil. 
The absolute contraction force (milligrams) gen- 
erated to increasing concentrations of serotonin and 
norepinephrine and relaxation to sodium nitroprus- 
side were significantly higher in hypercholester- 
olemic controls than in normocholesterolemic ani- 
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reals. This enhanced contractile response was 
reversed in verapamil-treated grafts, with the ob- 
served reduction in generated force being significant 
for all studied agonists (Table IV). The maximal 
response to a high KC1 (60 mmol/L) solution was 
highly variable; therefore the higher contraction 
observed in hypercholesterolemic grafts was not 
statistically significant. Contraction responses were 
then adjusted to the maximal KCl-induced contrac- 
tion (Table V). Adjusted contraction to serotonin 
was significantly enhanced by h percholesterolemia, 
and verapamil treatment resulted in significantly 
reduced contraction force to serotonin, at levels 
similar to those of normocholesterolemic controls 
(Fig. 6). Both KCl-adjusted contraction t  norepi- 
nephrine and relaxation of precontracted grafts to 
sodium nitroprusside were similar in control and 
verapamil-treated grafts. 
Discussion 
The present study demonstrates the ability of a 
polymeric targeted rug delivery system implanted 
at surgery to inhibit intimal proliferation in experi- 
mental vein grafts. Local effects included a signifi- 
cant reduction in neointimal SMC mass and density 
and a more favorable graft remodeling, expressed by 
reduced intima/media ratio and narrowing of the 
original lumen (percent stenosis). A distal down- 
stream effect was also noted, consisting mainly of 
improvement in some of the vasomotor abnormali- 
ties induced by vein arterialization and hypercholes- 
terolemia. This effect was achieved with an average 
drug release rate of 10/xg/day, less than 1% of the 
intravenous dose used by E1-Sanadiki and associ- 
ates 11 to achieve asimilar effect. In addition to being 
both safe and therapeutic, the system facilitated 
vessel ocalization and dissection at reoperation. 
After implantation i the arterial circulation, both 
human and experimental vein grafts undergo a type 
II vascular injury, characterized by endothelial and 
intimal damage. Patchy endothelial denuding seen 
immediately after implantation results in loss of the 
critical inhibitory effect of this layer on SMC 
growth. 16 As early as 1 hour after the operation, 
adherence of blood-borne cells, particularly plate- 
lets and monocytes, initiates an inflammatory cas- 
cade within the vessel wall. 2 Under the influence of 
locally secreted growth factors such as PDGF and 
transforming rowth factor-/3, medial SMCs un- 
dergo a phenotypic change from the contractile to a 
synthetic phenotype, resulting in migration and in- 
timal proliferation of the modified "myointimal" 
Fig. 5. Representative transmission electron micro- 
graphs of vein graft intima. All visualized cells are 
proliferated smooth muscle cells. A, Directly under 
empty control EVA matrices. B, Under verapamil-EVA 
matrices. C, Distal segments of verapamil-treated 
grafts. 
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Table II. Neointimal SMC content in proximal and 
downstream verapamil-treated and control vein graft 
segments 
HC ...... l HCVproximal HCVatst~t 
Intimal SMC density (%) 45.4 _+ 6.7 28.2 +_ 6.4* 33.0 -+ 7.3* 
Net intimal SMC (/xm) 174 _+ 49 88 -+ 25* 153 + 59 
Matrix and foam cells (/xm) 216 -+ 81 229 + 57 303 _+ 59? 
SMC, Smooth muscle cells. Values are the mean -+ standard eviation. 
*p < 0.01 compared with HC~o,,rol segments. 
"~p < 0.05 compared with HC~ontro~ andp = 0.01 compared with HCVp~o~im~l 
segments. 
Table IlL Sensitivity of norrnocholesterolemic, 
hypercholesterolemic control, and verapamil-treated 
distal vein graft segments 
NC HC~ont~ot HCVaist~t 
Serotonin 5.39 + 0.28 6.35 + 0.29 5.80 _+ 0.38* 
Norepinephrine 5.60 _+ 0.79 5.01 _+ 0.71 5.94 _+ 0.85? 
Sodium nitroprusside 11.68 _+ 0.54:) 10.62 -+ 0.43 10.74 + 0.45 
The sensitivity of normocholesterolemic (NC), hypercholesterolemic con- 
trols (HCco,,trol), and verapamil-treated (HCVa~tal) vein grafts to various 
agonists is expressed as -logl0(EDs0). Values represent the mean _+ 
standard eviation. 
*p = 0.002 and tp = 0.04 compared with HC~on,,.m segments. 
:~p < 0.05 compared with both hypercholesterolemic segments. 
cells. 16 In saphenous vein grafts, the early fibrointi- 
mal hyperplastic process directly results in signifi- 
cant graft narrowing (a 25% reduction in luminal 
diameter at 1 year is common) and is considered 
responsible for the subacutc graft occlusions een in 
10% of grafts 1 to 12 months after the operation. 3 
However, the proliferative phase is short-lived, 
peaking at 2 to 21 days in rodents and 1 to 12 
months in human beings, after which return to a 
quiescent chronic phase is seen. In the rabbit, no 
further increase in intimal cell mass and DNA 
content occurs after 4 weeks, and subsequent in- 
crease in wall mass and late remodeling are due to 
connective tissue accumulation and deposition of 
lipid, for which vein grafts seem to have a high 
affinity.2, 3,17 On this basis it has been assumed that 
successful interference with the early proliferative 
burst may have a beneficial effect on intermediate 
and late graft patency, but the latter remains cur- 
rently unproved. Documentation of late progression 
of intimal hyperplasia to atherosclerosis in mature 
grafts is largely based on indirect angiographic fol- 
low-up, and it is not known whether sites of foam 
cell deposition are the specific precursor lesions to 
the fully developed complex atherosclerotic plaque. 3
Although hypercholesterolemia does not seem to 
Table IV. Maximal absolute contraction/relaxation 
force (rag) of normocholesterolemic, 
hypercholesterolemic control, and verapamil-treated 
vein graft segments 
NC HCcontro l HCVdistal 
KC1 60 mmol/L 289 _+ 104 510 _+ 311 380 _+ 340 
Serotonin 381 -- 206 2111 _+ 400* 1369 _+ 666§ 
Norepinephrine 253 +_ 157 531 _+ 296? 298 _+ 1991] 
Sodium nitroprusside 329 _+ 196 768 _+ 31% 421 _+ 269¶ 
Values represent the mean +- standard eviation. 
*p = 8 × 10 -1°, tp = 0.034, and Sp = 0.005 compared with normocho- 
lesterolemic (NC) segments. 
§p = 0.012, ]p = 0.048, and ¶p = 0.018 compared with hypercholester- 
olemic control (HCcon,rol) segments. 
Table V. Maximal contraction/relaxation f rce of 
normocholesterolemic, hypercholesterolemic control, 
and verapamil-treated vein grafts, expressed as 
percent of KCl-induced maximal contraction 
NC HCco,,ro l HCVals,ot 
Serotonin 270 _+ 112 603 _+ 363 274 _+ 152" 
Norepinephrine 183 -+ 127 101 -+ 62 131 -+ 96 
Sodium nitroprusside 218 _+ 209 192 _+ 119 187 _+ 181 
Values represent the mean -+ standard eviation. 
*p = 0.008 compared with hypercholesterolemic control (HCcon~rol) seg- 
ments. 
have an additional direct mitogenic effect on SMCs, 
it dramatically accentuates intimal hyperplasia in 
rabbits, chiefly because of accumulation of lipid- 
laden macrophages (foam cells) in the subendothe- 
lial intima) 7' is The resulting morphologic appear- 
ance of fatty plaques resembles that seen in early 
atherosclerotic lesions in human vein grafts. Within 
4 weeks, the great increase in intimal mass allows 
sensitive quantitation of cellular and structural com- 
ponents and facilitates detection of the benefits of 
therapeutic nterventions. The rapid course of accel- 
erated atherosclerosis in hypercholesterolemic rab- 
bit autologous vein grafts thus promoted the wide- 
spread use of this model for the study of possible 
therapeutic nterventions. 
Toes and coworkers 19 recently reported success- 
ful inhibition of intimal and medial thickening in 
vein grafts by topical application of a sulfated car- 
bohydrate polymer gel capable of absorbing hepa- 
rin-binding growth factors. A potentially valuable 
option in peripheral vascular surgery, this semiliquid 
polymer elies on adjacent tissues for persistent con- 
tact with the vessel wall, making it less suitable for use 
in the pericardial cavity. The EVA system's features 
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Fig. 6. Dose-response contraction curves to serotonin in distal vein graft segments. Values are percent of 
KCl-induced maximal contraction and are expressed as mean - standard error of the mean.  HCcontrol, 
Hypercholesterolemic vein graft segments, distal to empty polymers; HVCdmaz, hypercholesterolemic vein 
graft segments distal to verapamil-EVA polymers; NC, normocholesterolemic graft midsegments. 
make it attractive for use in coronary revascularization. 
This polymer, approved by the Food and Drug Ad- 
ministration, isboth solid and highly flexible. In addi- 
tion to easy application and optimal suture handling, 
these physical properties result in protection of the 
treated vessel against accidental injury. Drug release is 
unilaterally targeted to the adventitia by sealing one 
surface with blank EVA film. Determination of the 
drug release kinetics in physiologic buffer correlates 
highly with in vivo delivery and is useful to prospec- 
tively design suitable systems for any given application 
and animal size. By varying matrix drug loads, surface 
area, and thickness, the rate and duration of drug 
delivery can be adjusted over a wide range. 8Moreover, 
the study of neointimal hyperplasia mechanisms i
facilitated by embedding hydrolyzable or metaboliz- 
able experimental gents in a hydrophobic polymeric 
controlled-release matrix. Such experimental gents 
(e.g., growth factors 2°'21 and their inhibitors 9'1°) 
would degrade when administered systemically, mak- 
ing this approach the only practical solution for exam° 
ining longitudinal in vivo effects. 
The calcium-channel blocker verapamil was used 
in the present study because of its widespread 
clinical availability and well-established inhibitory 
effects in animal models of atherosclerosis. 13' 14 The 
mechanism of antiatherogenic action of calcium 
channel antagonists i not entirely clear but may be 
due in part to direct inhibition of PDGF action. 
Verapamil has been shown to inhibit both indepen- 
dent and PDGF-induced SMC proliferation and 
migration in culture in a dose-dependent man- 
ner.ll, 12, 14 In injured rabbit arteries, potent and 
selective inhibition of SMC proliferation occurs only 
when administration of these agents is begun early 
after injury, suggesting an interference at the G0/G1 
phase of the cell cycle, possibly by prevention of 
modulation from the contractile to a synthetic phe- 
notypeJ 3Systemic administration ofverapamil (1.25 
mg/day) has been shown to reduce vein graft intimal 
proliferation in normocholesterolemic rabbits, 11 
suggesting a direct inhibitory effect on intimal SMC 
proliferation in vivo that is independent of lipid 
accumulation. In the setting of hypercholesterol- 
emia, an additional antiatherogenic action of vera- 
pamil may be due to an antioxidant effect on low- 
density lipoprotein cholesterol and to a decrease in 
intracellular lipid accumulation mediated by a cyclic 
adenosine diphosphate-dependent up-regulation of 
cholesteryl ester hydrolase. 22 
In the present study, significant reduction in vein 
graft intimal hyperplasia was observed in the seg- 
6 2 Brauner et aL 
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ments directly beneath verapamil-EVA matrices. 
This effect consisted mainly of inhibition of neoin- 
timal SMC proliferation, with little or no effect on 
lipid accumulation, as shown by the similar amount 
of foam cells and matrix observed in both wrapped 
groups. External support stents have been reported 
to have a beneficial effect on vein graft arterializa- 
tion in pigs 6 and in hypercholesterolemic rab- 
bits.23, 24 In particular, in a rabbit model similar to 
our own, intimal lipid and foam cell accumulation 
was significantly reduced in vein segments wrapped 
in polytetrafluoroethylene wh n compared with dis- 
tal unwrapped segments. 2sUnlike the matrices in 
the current study, however, these stents were de- 
signed to decrease wall tension by restricting vein 
graft distention to a predefined external diameter (4 
ram), often resulting in significant reduction in 
lumen size in addition to overall wall thickness. 
Moreover, Violaris and colleagues 26noted that ex- 
ternal stenting of pig vein grafts resulted in some 
reduction of medial hyperplasia but also in in- 
creased intimal thickness and significant narrowing 
of the lumen (percent stenosis). They concluded 
that this technique is unlikely to be beneficial. 
Nevertheless, our results how reduced intimal dep- 
osition of lipid and lipid-laden cells in both vera- 
pamil-EVA and control-EVA wrapped segments 
when compared with the distal unwrapped segments 
of verapamit-treated grafts, suggesting a local ben- 
eficial effect of the polymer on intimal lipid accu- 
mulation. It seems unlikely, however, that this effect 
was due solely to physical external restriction, be- 
cause overall graft diameter was similar under and 
distal to the verapamil-EVA polymers and was at 
least 1 mm smaller than the inner diameter of the 
applied devices. Moreover, the significant morpho- 
logic differences between vein graft segments di- 
rectly under verapamil versus control matrices ug- 
gest a specific local effect of the drug, independent 
of any action of the polymer device. 
In addition to structural remodeling, vein grafts 
undergo phenotypic changes that express as alterations 
in vasomotor function. Of these, the most prominent is
a de novo expression of a serotonin type 2 (5-hydroxy- 
tryptamine 2) receptor. 27 The resulting contraction 
response to serotonin, not observed in normal veins, 
has been quantitatively associated with the time-de- 
pendent development ofvein graft intimal hyperplasia 
as expressed by the intimal index. 27 Hypercholesterol- 
emia further enhances both contraction and sensitivity 
of rabbit vein grafts to serotonin, is' 28, 29 In the present 
study, periadventitial dministration of verapamil in 
hypercholesterolemic rabbits ignificantly reduced vein 
graft contraction and sensitivity to serotonin when 
compared with grafts treated with control empty ma- 
trices. Absolute contractile response to all agonists was 
also decreased. These effects were observed istal to 
the region of local drug delivery and were not accom- 
panied by a reduction in measured neointimal size or 
net intimal SMC mass in that segment, suggesting that 
either a change in SMC phenotype or interference by 
verapamil with the vasomotor action of serotonin has 
occurred. The latter seems less likely, because vera- 
pamil does not affect serotonin-induced contraction i
isolated arteries. 3° 
A progressive decrease in sensitivity (but not 
contraction force) to norepinephrine has also been 
demonstrated in normocholesterolemic arterialized 
rabbit veins and became significant 4 weeks after 
implantation.2S, 31, 32 However, hypercholesterol- 
emia seemed to induce a supersensitivity to norepi- 
nephrine at 4 weeks in at least one report, 28 a result 
that was not reproduced by our findings. In the 
present study, a slight decrease in both sensitivity 
and contraction to norepinephrine was observed in 
hypercholesterolemic control grafts, and the sensi- 
tivity (but not contraction) to norepinephrine in 
hypercholesterolemic vein grafts was significantly 
increased by verapamil treatment. Maximal relax- 
ation to sodium nitroprusside was similar in all 
grafts, but the sensitivity was significantly de- 
creased in both treated and control hypercholes- 
terolemic grafts. The significance of observed 
alterations in norepinephrine and sodium nitro- 
prusside vasoreactivity in rabbit vein grafts is not 
clear, and an association with intimal thickness or 
SMC mass was not documented. 29 In addition, 
because of the short graft length in the rabbit 
model, it cannot be determined whether the ef- 
fects observed istal to the region of matrix application 
are due to drug secretion to the bloodstream or to 
local diffusion within the vessel wall. 
The ability of a periadventitial drug delivery system 
to locally generate specific inhibition of neointimal 
SMC proliferation presents a potentially convenient 
alternative to systemic drug administration for both 
therapeutic and research purposes. This method 
seems readily applicable in coronary revascularization 
operations. Further evaluation of delivery systems with 
various agents and doses may optimize this approach 
for the purpose of clinical use. 
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